A Phase 4 interventional study of Netarsudil Ophthalmic Solution 0.02% in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-29.
Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 4, and was the 9th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Brett King · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Center for Sight Las Vegas · Sites in United States
Ages 40+
By country, each count listing its studies:
netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2018.
This study's enrollment of 261 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 85 across the 17 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Aerie Pharmaceuticals, one of the names counted as Alcon. Under that name alone:
Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 34th largest by enrollment of the 112 interventional ones that give a count, is the only one that started in 2018, is one of 31 in phase 4, and was the 119th registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
2 of the studies testing netarsudil in Glaucoma, Open-Angle that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07048886Center for Sight Las VegasRocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) | 2026-12-31 |
| NCT07325240Mayo Clinic24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, from their registry updates:
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-label design. The patients will receive treatment for 12 weeks.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Netarsudil Ophthalmic Solution 0.02%
1 drop in each eye once daily in the evening
Also known as: Rhopressa
Intraocular Pressure (IOP)
Percent Change from Baseline IOP at Week 12, as measured by Goldmann applanation tonometry. Prostaglandin analog (PGA). Fixed dose combination (FDC).
Time frame: 12 weeks
A total of 261 subjects were enrolled across 22 investigational sites and 260 treated.
| Milestone | Netarsudil Ophthalmic Solution 0.02% Monotherapy | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy |
|---|---|---|
| Started | 99 | 161 |
| Completed | 81 | 138 |
| Not completed | 18 | 23 |
| Withdrew: Adverse event | 13 | 17 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Intolerance to conjunctival hyperemia | 1 | 0 |
| Withdrew: Iop too high | 1 | 1 |
| Withdrew: Iop too high, nerve/visual field changes | 0 | 1 |
| Withdrew: Visit out of window | 0 | 1 |
| Withdrew: Medication non-compliance | 0 | 1 |
Percent Change from Baseline IOP at Week 12, as measured by Goldmann applanation tonometry. Prostaglandin analog (PGA). Fixed dose combination (FDC).
| percent change | Netarsudil Ophth Sol 0.02% Monotherapy - Tx Naïve At Baseline | Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 1 Agent | Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 2 Agents | Netarsudil Ophth Sol 0.02% Concomitant Therapy |
|---|---|---|---|---|
| Intraocular Pressure (IOP) | -16.9 ± 16.35 | -2.3 ± 16.23 | 0.2 ± 8.81 | -17.0 ± 16.81 |
Collected over Adverse event data was collected during the course of the 12-week treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Netarsudil Ophthalmic Solution 0.02% Monotherapy | 0/99 (0%) | 2/99 (2%) | 43/99 (43.4%) |
| Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | 0/161 (0%) | 1/161 (0.6%) | 58/161 (36%) |
| Event | Netarsudil Ophthalmic Solution 0.02% Monotherapy | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy |
|---|---|---|
| Malignant Melanoma of EyelidNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/99 | 0/161 |
| PneumoniaInfections and infestations | 1/99 | 0/161 |
| Cellulitis Lower Left ExtremityInfections and infestations | 0/99 | 1/161 |
| Event | Netarsudil Ophthalmic Solution 0.02% Monotherapy | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy |
|---|---|---|
| Conjunctival HyperemiaEye disorders | 22/99 | 32/161 |
| Vision BlurredEye disorders | 9/99 | 10/161 |
| Conjunctival HemorrageEye disorders | 6/99 | 8/161 |
| Instillation Site PainEye disorders | 6/99 | 8/161 |
Modified intent to treat (mITT) population included all subjects who received at least 1 dose of study medication and had at least 1 follow-up visit with a completed IOP measurement.
| Age, Continuous(years) | Netarsudil Ophthalmic Solution 0.02% Monotherapy | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | Total |
|---|---|---|---|
| Mean | 67.2 ± 11.85 | 67.2 ± 10.53 | 67.2 ± 11.02 |
| Sex: Female, Male(Participants) | Netarsudil Ophthalmic Solution 0.02% Monotherapy | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | Total |
|---|---|---|---|
| Female | 57 | 91 | 148 |
| Male | 34 | 60 | 94 |
| Ethnicity (NIH/OMB)(Participants) | Netarsudil Ophthalmic Solution 0.02% Monotherapy | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 8 | 19 |
| Not Hispanic or Latino | 80 | 143 | 223 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Netarsudil Ophthalmic Solution 0.02% Monotherapy | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 45 | 58 |
| White | 77 | 102 | 179 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Jul 2019, 6 months.
Results were first posted in Sep 2020, 1 year 2 months after primary completion.
Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil